Skip to main content
  • ASM
    • Antimicrobial Agents and Chemotheraphy
    • Applied and Environmental Mircobiology
    • Clinical Microbiology Reviews
    • Clinical and Vaccine Immunology
    • EcoSal Plus
    • Eukaryotic Cell
    • Infection and Immunity
    • Journal of Bacteriology
    • Journal of Clinical Microbiology
    • Journal of Microbiology & Biology Education
    • Journal of Virology
    • mBio
    • Microbiology and Molecular Biology Reviews
    • Microbiology Resource Announcements
    • Microbiology Spectrum
    • Molecular and Cellular Biology
    • mSphere
    • mSystems
  • Log in
  • My alerts
  • Log out
  • My Cart

Main menu

  • Home
  • Articles
    • Current Issue
    • Accepted Manuscripts
    • Archive
    • Minireviews
  • For Authors
    • Submit a Manuscript
    • Scope
    • Editorial Policy
    • Submission, Review, & Publication Processes
    • Organization and Format
    • Errata, Author Corrections, Retractions
    • Illustrations and Tables
    • Nomenclature
    • Abbreviations and Conventions
    • Publication Fees
    • Ethics Resources and Policies
  • About the Journal
    • About JCM
    • Editor in Chief
    • Editorial Board
    • For Reviewers
    • For the Media
    • For Librarians
    • For Advertisers
    • Alerts
    • RSS
    • FAQ
  • Subscribe
    • Members
    • Institutions
  • ASM
    • Antimicrobial Agents and Chemotheraphy
    • Applied and Environmental Mircobiology
    • Clinical Microbiology Reviews
    • Clinical and Vaccine Immunology
    • EcoSal Plus
    • Eukaryotic Cell
    • Infection and Immunity
    • Journal of Bacteriology
    • Journal of Clinical Microbiology
    • Journal of Microbiology & Biology Education
    • Journal of Virology
    • mBio
    • Microbiology and Molecular Biology Reviews
    • Microbiology Resource Announcements
    • Microbiology Spectrum
    • Molecular and Cellular Biology
    • mSphere
    • mSystems

User menu

  • Log in
  • My alerts
  • Log out
  • My Cart

Search

  • Advanced search
Journal of Clinical Microbiology
publisher-logosite-logo

Advanced Search

  • Home
  • Articles
    • Current Issue
    • Accepted Manuscripts
    • Archive
    • Minireviews
  • For Authors
    • Submit a Manuscript
    • Scope
    • Editorial Policy
    • Submission, Review, & Publication Processes
    • Organization and Format
    • Errata, Author Corrections, Retractions
    • Illustrations and Tables
    • Nomenclature
    • Abbreviations and Conventions
    • Publication Fees
    • Ethics Resources and Policies
  • About the Journal
    • About JCM
    • Editor in Chief
    • Editorial Board
    • For Reviewers
    • For the Media
    • For Librarians
    • For Advertisers
    • Alerts
    • RSS
    • FAQ
  • Subscribe
    • Members
    • Institutions
Letter to the Editor

Xpert Ultra Can Unambiguously Identify Specific Rifampin Resistance-Conferring Mutations

Kamela C. S. Ng, Armand van Deun, Conor J. Meehan, Gabriela Torrea, Michèle Driesen, Siemon Gabriëls, Leen Rigouts, Emmanuel André, Bouke C. de Jong
Karen C. Carroll, Editor
Kamela C. S. Ng
Unit of Mycobacteriology, Department of Biomedical Sciences, Institute of Tropical Medicine, Antwerp, Belgium
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Kamela C. S. Ng
Armand van Deun
Unit of Mycobacteriology, Department of Biomedical Sciences, Institute of Tropical Medicine, Antwerp, BelgiumInternational Union against Tuberculosis and Lung Disease, Paris, France
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Conor J. Meehan
Unit of Mycobacteriology, Department of Biomedical Sciences, Institute of Tropical Medicine, Antwerp, Belgium
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Conor J. Meehan
Gabriela Torrea
Unit of Mycobacteriology, Department of Biomedical Sciences, Institute of Tropical Medicine, Antwerp, Belgium
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Gabriela Torrea
Michèle Driesen
Unit of Mycobacteriology, Department of Biomedical Sciences, Institute of Tropical Medicine, Antwerp, Belgium
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Michèle Driesen
Siemon Gabriëls
Unit of Mycobacteriology, Department of Biomedical Sciences, Institute of Tropical Medicine, Antwerp, Belgium
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Leen Rigouts
Unit of Mycobacteriology, Department of Biomedical Sciences, Institute of Tropical Medicine, Antwerp, BelgiumDepartment of Biomedical Sciences, University of Antwerp, Antwerp, Belgium
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Leen Rigouts
Emmanuel André
Laboratory of Clinical Bacteriology and Mycology, KU Leuven, Leuven, Belgium
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Emmanuel André
Bouke C. de Jong
Unit of Mycobacteriology, Department of Biomedical Sciences, Institute of Tropical Medicine, Antwerp, Belgium
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Bouke C. de Jong
Karen C. Carroll
Johns Hopkins University School of Medicine
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
DOI: 10.1128/JCM.00686-18
  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
Loading

LETTER

The deluge of data produced by the Xpert MTB/RIF test (Cepheid) can help improve global rifampin-resistant tuberculosis (RR-TB) control strategies through molecular epidemiological surveillance (1, 2). Recently, a new version of the test, Xpert Ultra (hereinafter called Ultra), was released (3). Determining the relationship between RR-conferring rpoB mutations, Ultra probes, and melting temperature shifts (ΔTm), i.e., the difference between mutant and wild-type melting temperatures, allows Ultra results to be utilized for rapid detection of RR-TB strains and related underlying rpoB mutations.

To determine the reliability of Ultra results for predicting specific mutations, we tested 13 rifampin-susceptible (RS)-TB strains and 104 RR-TB strains harboring 33 unique RR-conferring mutations from the Belgian Coordinated Collections of Microorganisms in the Institute of Tropical Medicine Antwerp according to a protocol previously described (2) (see the supplemental material). Of note, the Glu250Gly (n = 2) and Arg299Cys (n = 1) mutations were among the RS-TB strains. We then compared Ultra raw results with available rpoB sequences of the strains.

Overall, 29/30 (97%) mutations inside the rifampin resistance-determining region (RRDR) were correctly identified by Ultra. Of concern, mutation His445Arg gave a “RIF Resistance Indeterminate” result among 3/4 strains tested, while it was reported as RR in the initial validation study (3). The silent mutation Thr444Thr was not reported as RR (Fig. 1). The RR-conferring mutations on codons 170 and 491 situated outside the RRDR were not detected.

FIG 1
  • Open in new tab
  • Download powerpoint
FIG 1

Overview of Xpert Ultra test results. The observed probe reactions for each RRDR mutation were laid over the claimed probe coverage (light gray). Shown in black are probe reactions concordant with manufacturer claims, in blue are probe reactions missed by one probe but captured by another probe, and in red is a probe reaction representing a “RIF Resistance Indeterminate” result from 3 out of 4 strains tested. Results in the hatched pattern were superimposed for greater visibility.

The probe reactions observed were largely in agreement with previous results (3), although we noted that mutations Met434Val, Met434Thr, and those in codon 435 were captured only by probe rpoB2, Ser450Leu and Ser450Trp were captured by both probe rpoB3 and probe rpoB4a, His445Arg was captured only by probe rpoB3, and Lys446Gln was captured only by probe rpoB4.

All mutations except those in codon 450 were associated with a negative ΔTm (Fig. 2). The combination of ΔTm values with the capturing probes enabled us to differentiate mutations in codons 430, 431, 434, 435, 441, 446, 450, and 452, including disputed mutations (4) (Table 1). Mutation Asp435Tyr was unambiguously distinguished from Asp435Val with the ∣ΔTm∣ of probe rpoB2, while mutations Ser441Gln and Ser441Leu were discriminated from the rest by the ∣ΔTm∣ values of probes rpoB2 and rpoB3. Mutations His445Asp and His445Tyr were distinguished from disputed mutations His445Leu and His445Asn through the ∣ΔTm∣ of probe rpoB3. Ser450Leu was distinguished from Ser450Trp by the ∣ΔTm∣ of probe rpoB4A. The indeterminate result associated with His445Arg may be caused by its ∣ΔTm∣ being equal to 1.8°C, unlike the ∣ΔTm∣ values for other mutations, which typically exceed 2°C. Our recent experience with Ultra on diagnostic sputum samples pertained only to the Ser450Leu and His445Asp mutations, for which the ΔTm corresponded exactly with the ΔTm that we observed for bacterial thermolysates. This should be validated more extensively, which is beyond the scope of our present study.

FIG 2
  • Open in new tab
  • Download powerpoint
FIG 2

Melting temperature shifts (ΔTms) observed upon detection of a rifampin resistance (RR)-conferring rpoB mutation in the RR-determining region (RRDR) by Xpert Ultra. The y axis reflects the melting temperature difference (ΔTm) between mutant and wild-type probe-amplicon hybrids, while the x axis shows the mutations that we tested. The data points on the graph are ΔTm values grouped by their associated Ultra probes (differentiated by color), which correspond to a specific rpoB mutation. x axis labels in brown are disputed mutations.

View this table:
  • View inline
  • View popup
TABLE 1

Xpert Ultra raw resultsa

Our findings confirm the ability of Ultra to unambiguously identify a wide range of RRDR mutations. With the unprecedented rollout of Xpert MTB/RIF and associated connectivity solutions, such as DataToCare (Savics, Belgium) and GXAlert (SystemOne, USA) (2), Ultra results may allow us to rule out transmission between RR-TB patients in a specific setting (Fig. S1), distinguish relapse from reinfection (5) (Fig. S2), and resolve discordance between an RR Ultra result and a low-level RS phenotypic result due to a disputed mutation. For such applications, it is key that ΔTm values are included in the exported results.

ACKNOWLEDGMENT

This work was supported by Erasmus Mundus Joint Doctorate Fellowship grant 2016-1346 to K.C.S.N.

FOOTNOTES

    • Accepted manuscript posted online 20 June 2018.
  • Address correspondence to Kamela C. S. Ng, kng{at}itg.be.
  • E.A. and B.C.D.J. contributed equally to this work.

  • Citation Ng KCS, van Deun A, Meehan CJ, Torrea G, Driesen M, Gabriëls S, Rigouts L, André E, de Jong BC. 2018. Xpert Ultra can unambiguously identify specific rifampin resistance-conferring mutations. J Clin Microbiol 56:e00686-18. https://doi.org/10.1128/JCM.00686-18.

  • Supplemental material for this article may be found at https://doi.org/10.1128/JCM.00686-18.

REFERENCES

  1. 1.↵
    1. Andre E,
    2. Isaacs C,
    3. Affolabi D,
    4. Alagna R,
    5. Brockmann D,
    6. de Jong BC,
    7. Cambau E,
    8. Churchyard G,
    9. Cohen T,
    10. Delmee M,
    11. Delvenne JC,
    12. Farhat M,
    13. Habib A,
    14. Holme P,
    15. Keshavjee S,
    16. Khan A,
    17. Lightfoot P,
    18. Moore D,
    19. Moreno Y,
    20. Mundade Y,
    21. Pai M,
    22. Patel S,
    23. Nyaruhirira AU,
    24. Rocha LE,
    25. Takle J,
    26. Trebucq A,
    27. Creswell J,
    28. Boehme C
    . 2016. Connectivity of diagnostic technologies: improving surveillance and accelerating tuberculosis elimination. Int J Tuberc Lung Dis 20:999–1003. doi:10.5588/ijtld.16.0015.
    OpenUrlCrossRef
  2. 2.↵
    1. Ng KC,
    2. Meehan CJ,
    3. Torrea G,
    4. Goeminne L,
    5. Diels M,
    6. Rigouts L,
    7. de Jong BC,
    8. Andre E
    . 2018. Potential application of digitally linked tuberculosis diagnostics for real-time surveillance of drug-resistant tuberculosis transmission: validation and analysis of test results. JMIR Med Inform 6:e12. doi:10.2196/medinform.9309.
    OpenUrlCrossRef
  3. 3.↵
    1. Chakravorty S,
    2. Simmons AM,
    3. Rowneki M,
    4. Parmar H,
    5. Cao Y,
    6. Ryan J,
    7. Banada PP,
    8. Deshpande S,
    9. Shenai S,
    10. Gall A,
    11. Glass J,
    12. Krieswirth B,
    13. Schumacher SG,
    14. Nabeta P,
    15. Tukvadze N,
    16. Rodrigues C,
    17. Skrahina A,
    18. Tagliani E,
    19. Cirillo DM,
    20. Davidow A,
    21. Denkinger CM,
    22. Persing D,
    23. Kwiatkowski R,
    24. Jones M,
    25. Alland D
    . 2017. The new Xpert MTB/RIF Ultra: improving detection of Mycobacterium tuberculosis and resistance to rifampin in an assay suitable for point-of-care testing. mBio 8:e00812-17. doi:10.1128/mBio.00812-17.
    OpenUrlAbstract/FREE Full Text
  4. 4.↵
    1. van Deun A,
    2. Aung KJ,
    3. Bola V,
    4. Lebeke R,
    5. Hossain MA,
    6. de Rijk WB,
    7. Rigouts L,
    8. Gumusboga A,
    9. Torrea G,
    10. de Jong BC
    . 2013. Rifampin drug resistance tests for tuberculosis: challenging the gold standard. J Clin Microbiol 51:2633–2640. doi:10.1128/JCM.00553-13.
    OpenUrlAbstract/FREE Full Text
  5. 5.↵
    1. Rosser A,
    2. Marx FM,
    3. Pareek M
    . 2018. Recurrent tuberculosis in the pre-elimination era. Int J Tuberc Lung Dis 22:139–150. doi:10.5588/ijtld.17.0590.
    OpenUrlCrossRef
  6. 6.
    1. Coll F,
    2. Phelan J,
    3. Hill-Cawthorne GA,
    4. Nair MB,
    5. Mallard K,
    6. Ali S,
    7. Abdallah AM,
    8. Alghamdi S,
    9. Alsomali M,
    10. Ahmed AO,
    11. Portelli S,
    12. Oppong Y,
    13. Alves A,
    14. Bessa TB,
    15. Campino S,
    16. Caws M,
    17. Chatterjee A,
    18. Crampin AC,
    19. Dheda K,
    20. Furnham N,
    21. Glynn JR,
    22. Grandjean L,
    23. Minh Ha D,
    24. Hasan R,
    25. Hasan Z,
    26. Hibberd ML,
    27. Joloba M,
    28. Jones-Lopez EC,
    29. Matsumoto T,
    30. Miranda A,
    31. Moore DJ,
    32. Mocillo N,
    33. Panaiotov S,
    34. Parkhill J,
    35. Penha C,
    36. Perdigao J,
    37. Portugal I,
    38. Rchiad Z,
    39. Robledo J,
    40. Sheen P,
    41. Shesha NT,
    42. Sirgel FA,
    43. Sola C,
    44. Oliveira Sousa E,
    45. Streicher EM,
    46. Helden PV,
    47. Viveiros M,
    48. Warren RM,
    49. McNerney R,
    50. Pain A,
    51. Clark TG
    . 2018. Genome-wide analysis of multi- and extensively drug-resistant Mycobacterium tuberculosis. Nat Genet 50:307–316. doi:10.1038/s41588-017-0029-0.
    OpenUrlCrossRef
  7. 7.
    1. Sandgren A,
    2. Strong M,
    3. Muthukrishnan P,
    4. Weiner BK,
    5. Church GM,
    6. Murray MB
    . 2009. Tuberculosis drug resistance mutation database. PLoS Med 6:e2. doi:10.1371/journal.pmed.1000002.
    OpenUrlCrossRefPubMed
  • Copyright © 2018 Ng et al.

This is an open-access article distributed under the terms of the Creative Commons Attribution 4.0 International license.

PreviousNext
Back to top
Download PDF
Citation Tools
Xpert Ultra Can Unambiguously Identify Specific Rifampin Resistance-Conferring Mutations
Kamela C. S. Ng, Armand van Deun, Conor J. Meehan, Gabriela Torrea, Michèle Driesen, Siemon Gabriëls, Leen Rigouts, Emmanuel André, Bouke C. de Jong
Journal of Clinical Microbiology Aug 2018, 56 (9) e00686-18; DOI: 10.1128/JCM.00686-18

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Print

Alerts
Sign In to Email Alerts with your Email Address
Email

Thank you for sharing this Journal of Clinical Microbiology article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
Xpert Ultra Can Unambiguously Identify Specific Rifampin Resistance-Conferring Mutations
(Your Name) has forwarded a page to you from Journal of Clinical Microbiology
(Your Name) thought you would be interested in this article in Journal of Clinical Microbiology.
Share
Xpert Ultra Can Unambiguously Identify Specific Rifampin Resistance-Conferring Mutations
Kamela C. S. Ng, Armand van Deun, Conor J. Meehan, Gabriela Torrea, Michèle Driesen, Siemon Gabriëls, Leen Rigouts, Emmanuel André, Bouke C. de Jong
Journal of Clinical Microbiology Aug 2018, 56 (9) e00686-18; DOI: 10.1128/JCM.00686-18
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Top
  • Article
    • LETTER
    • ACKNOWLEDGMENT
    • FOOTNOTES
    • REFERENCES
  • Figures & Data
  • Info & Metrics
  • PDF

KEYWORDS

Xpert MTB/RIF Ultra
rifampin-resistant tuberculosis
rpoB mutations
disputed mutations
Ultra probes
melt peak temperature (Tm)
melting temperature shift (ΔTm)

Related Articles

Cited By...

About

  • About JCM
  • Editor in Chief
  • Board of Editors
  • Editor Conflicts of Interest
  • For Reviewers
  • For the Media
  • For Librarians
  • For Advertisers
  • Alerts
  • RSS
  • FAQ
  • Permissions
  • Journal Announcements

Authors

  • ASM Author Center
  • Submit a Manuscript
  • Article Types
  • Resources for Clinical Microbiologists
  • Ethics
  • Contact Us

Follow #JClinMicro

@ASMicrobiology

       

ASM Journals

ASM journals are the most prominent publications in the field, delivering up-to-date and authoritative coverage of both basic and clinical microbiology.

About ASM | Contact Us | Press Room

 

ASM is a member of

Scientific Society Publisher Alliance

Copyright © 2019 American Society for Microbiology | Privacy Policy | Website feedback

Print ISSN: 0095-1137; Online ISSN: 1098-660X